E. Murakami

Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation

Y. Koh, N. Yamamoto, Y. Ozawa, 2021, Anticancer Research.

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer

Y. Koh, N. Yamamoto, Y. Ozawa, 2019, The oncologist.

Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.

Y. Koh, N. Yamamoto, Y. Ozawa, 2019, The oncologist.

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.

Y. Koh, N. Yamamoto, H. Akamatsu, 2018, Lung cancer.

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50

Y. Koh, N. Yamamoto, J. Fukuoka, 2020, Cancer science.

Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial

N. Yamamoto, H. Akamatsu, T. Shimokawa, 2019, BMJ Open.

Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors

Takanori Yoshikawa, Y. Koh, Y. Ozawa, 2022, Cancer Immunology, Immunotherapy.

O2-7-3Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

Y. Koh, N. Yamamoto, H. Akamatsu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin‐based chemotherapy using short hydration: A randomized phase II trial

H. Akamatsu, A. Hayata, R. Shibaki, 2024, Cancer medicine.

Furosemide versus mannitol in patients who received cisplatin-based chemotherapy using short hydration: study protocol for a randomized controlled trial

N. Yamamoto, H. Akamatsu, T. Shimokawa, 2018 .